
Co-Diagnostics (CODX) Stock Forecast & Price Target
Co-Diagnostics (CODX) Analyst Ratings
Bulls say
Co-Diagnostics Inc. is positioned favorably within the expanding market for respiratory infectious disease diagnostics, particularly due to significant investments in the Kingdom of Saudi Arabia and a strategic partnership through its Joint Venture, CoMira Diagnostics, which will enhance its capabilities in the region. The development of a proprietary sample preparation instrument aimed at reducing the cost of processing samples for point-of-care PCR testing showcases the company’s commitment to improving accessibility to essential health technologies globally. Additionally, ongoing advancements in their Co-Dx PCR platform, including the pursuit of regulatory clearances for a refined COVID-19 test, indicate a robust trajectory in expanding their product offerings and market presence.
Bears say
Co-Diagnostics Inc faces significant risks that could adversely impact its financial performance, including potential failures in clinical evaluations, regulatory clearances, and competition, which jeopardize its market penetration and commercial success. The company's recent financial results indicate a troubling trend, with revenue at only $145,000 for the third quarter of 2025, while incurring a net loss of $5.9 million, translating to a loss of $0.16 per share. Additionally, concerns regarding future fundraising imply increasing dilution and less favorable terms, further complicating the company's financial stability.
This aggregate rating is based on analysts' research of Co-Diagnostics and is not a guaranteed prediction by Public.com or investment advice.
Co-Diagnostics (CODX) Analyst Forecast & Price Prediction
Start investing in Co-Diagnostics (CODX)
Order type
Buy in
Order amount
Est. shares
0 shares